

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

NCT06577363

Status RECRUITING
Sponsor Takeda
Enrollment 250 participants

Key Eligibility Criteria

Inclusion (1)

- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

Exclusion (1)

- None

Locations (1 total)

Takeda selected site, Tokyo, Japan